Related references
Note: Only part of the references are listed.Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer
Susan Tsai et al.
ANNALS OF SURGERY (2020)
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Brent T. Xia et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis
Susanna W. L. de Geus et al.
SURGERY (2017)
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
M. Reni et al.
ANNALS OF ONCOLOGY (2017)
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival
Irene Epelboym et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer
Jennifer L. Williams et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2016)
Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study
John R. Bergquist et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head
Waseem Lutfi et al.
SURGERY (2016)
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
Cristina R. Ferrone et al.
ANNALS OF SURGERY (2015)
Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer
Ryan P. Merkow et al.
ANNALS OF SURGERY (2014)
The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma
Wenchuan Wu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
Brian A. Boone et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
Maximilian Bockhorn et al.
SURGERY (2014)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
Ching-Wei D. Tzeng et al.
HPB (2014)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew H. G. Katz et al.
CANCER (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Neoadjuvant Therapy Is Associated With Improved Survival in Resectable Pancreatic Adenocarcinoma
Avo Artinyan et al.
CANCER (2011)
PANCREATIC CANCER TUMOR SIZE ON CT SCAN VERSUS PATHOLOGIC SPECIMEN: IMPLICATIONS FOR RADIATION TREATMENT PLANNING
Nils D. Arvold et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy
TY Cheng et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients
KFCD Kuhlmann et al.
EUROPEAN JOURNAL OF CANCER (2004)
Share Paper
